Under terms of the agreement, the company will acquire the right to develop, manufacture and market products and processes derived from Trophic’s patent, which relates to solutions containing
The round was led by Venture Investors, with participants including Advantage Capital, several Wisconsin based angel investor groups, and a large private equity firm. Cellectar will use the
The Phase II program is designed to evaluate the safety and efficacy of NKTR-102 (PEG-irinotecan) for the treatment of patients with solid tumors. The first study in the
The acquisition is expected to strengthen the company’s position in advanced in- vitro diagnostic (IVD) market in China. The company expects the acquisition to be accretive immediately from
The trial will investigate the efficacy and safety of Relaxin in patients with acute heart failure. Approximately 330 patients will be recruited from more than 50 investigational centers
Banner has developed and is in the process of registering the products for the US market, and under the agreements Heritage is granted exclusive sales and marketing rights
The primary objective of the open label multi-center Phase II study is to characterize safety of Interleukin 21 (IL-21) with Nexavar at the recommended dose; a secondary objective
Under the terms of the agreement, Sol-Gel Technologies will receive $24.7 million, comprised of an initial non-refundable payment as well as additional payments upon the successful completion of
The primary efficacy endpoint of the study is reduction of hemolysis from baseline. The study will also measure the effect of Soliris on other clinical manifestations of paroxysmal
The company enrolled 551 obese patients at multiple clinical sites in the US for a six-month, randomized, placebo-controlled dose ranging study. The study is designed to evaluate three
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.